Kalytera Therapeutics Inc.(TSX:V.KALY, KALTF,
Forum) announced Tuesday that it is developing a unique cannabinoid-based compound for the treatment of acute and chronic pain.
Kalytera has obtained an exclusive, worldwide license for this compound from Israeli-based pharmaceutical company
Beetlebung Pharma, Ltd. The compound consists of a cannabinoid coupled with naproxen, a generic, non-steroidal, anti-inflammatory drug that is already approved for pain treatment.
More information can be found
here.
Kalytera Therapeutics was in the news recently when the Company said it had granted stock options to certain officers of the Company - Chief Scientific Officer Dr. Sari Prutchi-Sagiv and Chief Medical Officer Dr. Moshe Yeshurun.
FULL DISCLOSURE: Kalytera Therapeutics Inc. is a paid client of Stockhouse Publishing.